What the Latest IgAN Clinical Trials Mean for Patient Care
On the Frontlines of IgA NephropathyWhat the Latest IgAN Clinical Trials Mean for Patient Care
Steve Jackson, PharmD
Andrew S. Bomback, MD, MPH
Gates B. Colbert, MD
Anjay Rastogi, MD, PhD
Targeting BAFF and APRIL in IgA Nephropathy
On the Frontlines of IgA NephropathyTargeting BAFF and APRIL in IgA Nephropathy
Gates B. Colbert, MD
Edgar V. Lerma, MD, FACP, FASN, FPSN (Hon)
Early Combination Therapy in IgA Nephropathy
On the Frontlines of IgA NephropathyEarly Combination Therapy in IgA Nephropathy
Gates B. Colbert, MD
Sayna Norouzi, MD
Reading the Warning Signs: Risk Stratification in IgAN
On the Frontlines of IgA NephropathyReading the Warning Signs: Risk Stratification in IgAN
Gates B. Colbert, MD
Dustin Le, MD, MHS
Not Just for Diabetes: Broadening uACR Screening to CV Risk Populations
Conversations in CV Risk AssessmentNot Just for Diabetes: Broadening uACR Screening to CV Risk Populations
Brian P. McDonough, MD, FAAFP
Anu Lala, MD
- advertisement
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
CME/CENo Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
Brendon Neuen, MBBS, PhD
Katherine Tuttle, MD
Optimizing Outcomes in Patients with FSGS: A Case-Based Approach in the New Era of Targeted Therapy
CME/CEOptimizing Outcomes in Patients with FSGS: A Case-Based Approach in the New Era of Targeted Therapy
Jörg Latus, MD
Sayna Norouzi, MD
Engaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
CME/CEEngaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
Sayna Norouzi, MD
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
CME/CETranslating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Aldosterone-Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease
CME/CEAldosterone-Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease
Jamie P. Dwyer, MD
J. Matthew Luther, MD, MSCI
Vivek Bhalla, MD
Continuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
CME/CEContinuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
Christian Mende, MD, FACP, FACN, FASN, FASH, FAHA
Deepak Bhatt, MD, MPH, MBA, FACC, FAHA
- advertisement
Not Just for Diabetes: Broadening uACR Screening to CV Risk Populations
Conversations in CV Risk AssessmentNot Just for Diabetes: Broadening uACR Screening to CV Risk Populations
Brian P. McDonough, MD, FAAFP
Anu Lala, MD
Unseen Disease: The Diagnostic Barriers to CKD and CV Risk Prevention
Conversations in CV Risk AssessmentUnseen Disease: The Diagnostic Barriers to CKD and CV Risk Prevention
Jennifer Caudle, DO, FACOFP
Dustin Le, MD, MHS
Niloo Nobakht, MD, FASN
Predicting the Heart’s Future: Albuminuria as a CV Warning Sign
Conversations in CV Risk AssessmentPredicting the Heart’s Future: Albuminuria as a CV Warning Sign
Brian P. McDonough, MD, FAAFP
Anu Lala, MD
Heart Failure and Albuminuria: Connecting the Dots
Conversations in CV Risk AssessmentHeart Failure and Albuminuria: Connecting the Dots
Jennifer Caudle, DO, FACOFP
Robert J. Mentz, MD, FHFSA, FACC
Bridging the Gap: From Screening to Cardiovascular Risk Diagnosis
Conversations in CV Risk AssessmentBridging the Gap: From Screening to Cardiovascular Risk Diagnosis
Jennifer Caudle, DO, FACOFP
Dustin Le, MD, MHS
Niloo Nobakht, MD, FASN
The Risk Equation: Combining uACR and eGFR for CV Prediction
Conversations in CV Risk AssessmentThe Risk Equation: Combining uACR and eGFR for CV Prediction
Matthew Sorrentino, MD
Ashish Verma, MBBS
- 07/30/2026
- 07/29/2026
- 07/14/2026
- 07/14/2026
- 07/10/2026
- 07/03/2026